Bellmann Caren, Unnebrink Kristina, Rubin Gary S, Miller Daniel, Holz Frank G
Department of Ophthalmology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):968-74. doi: 10.1007/s00417-003-0689-6. Epub 2003 Sep 6.
Patients with advanced age-related macular degeneration (AMD) suffer not only from impairment in central visual acuity (VA), but also from reduction in contrast sensitivity (CS). We examined VA and CS changes over time in patients with subfoveal choroidal neovascularizations (CNV) as well as the correlation between the two parameters.
VA was determined according to a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) chart. CS was measured with Pelli-Robson charts. The angiographic characteristics of CNV and the presence of CNV in the fellow eye as well as gender and age were evaluated as possible prognostic factors of VA and CS progression. Two hundred and five patients with neovascular AMD were recruited within the Radiation Therapy for Age-Related Macular Degeneration (RAD) Study and were reviewed over 2 years. The treatment and control groups showed no significant difference for VA or for CS ( P>0.05), and both groups were considered together.
At baseline, mean VA was 55.6+/-14.5 SD letters (EDTRS chart), and mean CS was 22.8+/-6.9 letters (Pelli-Robson chart). Spearman Correlation Coefficient ( r(s)) between VA and CS was r(s)=0.60, P=0.0001. Over 2 years the mean VA loss was 23.6+/-21.4 letters and mean CS reduction was 9.0+/-9.7 letters. Agreement between change of VA and change of CS was moderate ( r(s)=0.65, P=0.0001; kappa coefficient (grouped into VA loss < or =15, >15, >30 letters; CS loss < or =6, >6, >15 letters) kappa=0.43, 95% CI [0.32;0.54]). Proportional hazard models did not show any apparent influence of type of CNV, or CNV in the fellow eye, on change in VA and CS.
The results indicate that VA and CS do not always show the same progression in visual function loss although they show a moderate correlation in eyes with neovascular AMD. Both parameters provide important information about visual disability and should be evaluated as outcome in interventional studies.
晚期年龄相关性黄斑变性(AMD)患者不仅中心视力(VA)受损,对比敏感度(CS)也降低。我们研究了黄斑下脉络膜新生血管(CNV)患者的VA和CS随时间的变化以及这两个参数之间的相关性。
根据标准化方案,使用早期糖尿病视网膜病变(ETDRS)视力表测定VA。使用佩利-罗布森视力表测量CS。评估CNV的血管造影特征、对侧眼CNV的存在情况以及性别和年龄,作为VA和CS进展的可能预后因素。在年龄相关性黄斑变性放射治疗(RAD)研究中招募了205例新生血管性AMD患者,并在2年时间内进行随访。治疗组和对照组在VA或CS方面无显著差异(P>0.05),两组合并分析。
基线时,平均VA为55.6±14.5标准差字母(EDTRS视力表),平均CS为22.8±6.9字母(佩利-罗布森视力表)。VA和CS之间的Spearman相关系数(r(s))为r(s)=0.60,P=0.0001。在2年时间里,平均VA损失为23.6±21.4字母,平均CS降低为9.0±9.7字母。VA变化和CS变化之间的一致性为中等(r(s)=0.65,P=0.0001;kappa系数(分为VA损失≤15、>15、>30字母;CS损失≤6、>6、>15字母)kappa=0.43,95%可信区间[0.32;0.54])。比例风险模型未显示CNV类型或对侧眼CNV对VA和CS变化有任何明显影响。
结果表明,虽然在新生血管性AMD眼中VA和CS在视觉功能丧失方面显示出中等相关性,但它们并不总是表现出相同的进展。这两个参数都提供了有关视觉残疾的重要信息,应作为干预研究的结果进行评估。